Cirrhosis News and Research

Latest Cirrhosis News and Research

Combining medications may increase HBsAg loss in HBV patients

Combining tenofovir disoproxil fumarate with pegylated interferon alfa-2a may improve the chances of hepatitis B surface antigen loss in patients with hepatitis B virus infection, suggests a randomised trial.

3 Dec 2015

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

A large multi-center clinical trial has found that a combination of antiviral medications can eradicate hepatitis C infection in more than 90 percent of patients with advanced liver disease. Known as the ASTRAL-4 trial, the study was co-led by investigators at Beth Israel Deaconess Medical Center and Intermountain Medical Center and published online Nov. 17 in The New England Journal of Medicine.

1 Dec 2015

Researchers reveal new technique to grow human hepatocytes in the laboratory

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for patients awaiting transplantations.

27 Nov 2015

Fewer than 1 in 3 UK hospitals employ full-time doctors specialized in liver medicine

Despite rising rates of alcohol- and obesity-related liver disease, fewer than 1 in 3 UK hospitals employ a full-time liver specialist

22 Nov 2015

New drug combination may reduce need for complex regimens to treat hepatitis C

The prognosis for people with hepatitis C has improved dramatically in the last few years, thanks to the introduction of direct-acting anti-viral medications, including Harvoni (the brand name for a combination of ledipasvir and sofosbuvir) and Viekira Pack (a mix of ombitasvir, paritaprevir, ritonavir and dasabuvir).

19 Nov 2015

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Nearly 50 percent of Medicaid patients infected with chronic hepatitis C whose doctors had prescribed newer, life-saving antiviral drugs were denied coverage to the therapies because they weren't considered "a medical necessity" or because the patients tested positive for alcohol/drugs, among other reasons, according to new Penn Medicine research.

17 Nov 2015

UC Irvine Health researchers develop one-step test to detect HCV infections

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the Annual Meeting of American Association for the Study of Liver Disease in San Francisco, Nov. 14-16. Current blood-based HCV testing requires two steps and can be expensive, inconvenient and is not widely available or affordable globally.

15 Nov 2015

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

In one of the greatest advances in medicine in decades, Hepatitis C is now largely curable. Over 200,000 Australians suffer from Hepatitis C. However the US manufacturer, Gilead Sciences Inc is attempting to charge the PBS $84,000 for a 12 week course of medication that costs under $200 dollars to manufacture.

13 Nov 2015

UT Southwestern's Helen H. Hobbs named recipient of Breakthrough Prize in Life Sciences

UT Southwestern Medical Center geneticist Dr. Helen H. Hobbs is the 2016 recipient of the prestigious Breakthrough Prize in Life Sciences.

10 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

SLU hepatologist receives $150,000 grant to study preventative strategies for TPN-associated disorders

When a child is born prematurely, providing nutrition intravenously can be lifesaver. Unfortunately it can also cause liver damage down the road.

29 Oct 2015

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.

12 Oct 2015

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient's immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

9 Oct 2015

Understanding HCV disease progression rates among PWID

The Hepatitis C virus (HCV) infection is a chronic blood-borne viral infection that affects an estimated 160 million people, or 2-3% of the population world-wide. Alarmingly, chronic HCV infection accounts for one-quarter of the cases of cirrhosis and hepatocellular carcinoma (HCC). If HCV is left untreated, chronic liver disease will occur in 60-70% of the cases, cirrhosis in 5-20% of the cases, and 1-5% will die from decompensated cirrhosis or HCC.

6 Oct 2015

Cirrhosis News and Research

Latest Cirrhosis News and Research

Combining medications may increase HBsAg loss in HBV patients

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

Researchers reveal new technique to grow human hepatocytes in the laboratory

Fewer than 1 in 3 UK hospitals employ full-time doctors specialized in liver medicine

New drug combination may reduce need for complex regimens to treat hepatitis C

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

UC Irvine Health researchers develop one-step test to detect HCV infections

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

UT Southwestern's Helen H. Hobbs named recipient of Breakthrough Prize in Life Sciences

New funding for Centenary's life saving research

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

SLU hepatologist receives $150,000 grant to study preventative strategies for TPN-associated disorders

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Understanding HCV disease progression rates among PWID

New trial results show efficacy of novel enzyme-replacement therapy for genetic lipid disorder

Researchers identify new virus that plays role in rare type of liver cancer

Yale study identifies new barrier to caring for chronic hepatitis C patients

Multi-national group of scientists developing new test for Hepatocellular Carcinoma

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cirrhosis News and Research

Latest Cirrhosis News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in